Canakinumab as first-line biological therapy in Still's disease and differences between the systemic and the chronic-articular courses: real-life experience from the international AIDA registry.

Vitale A;Caggiano V;Maggio MC;Lopalco G;Emmi G;Sota J;La Torre F;Ruscitti P;Bartoloni E;Conti G;Fabiani C;Mattioli I;Gaggiano C;Cardinale F;Dagna L;Campochiaro C;Giacomelli R;Balistreri A;Laskari K;Tufan A;Ragab G;Almaghlouth IA;Więsik-Szewczyk E;Pereira RM;Frediani B;Iannone F;Sfikakis PP;Cantarini L.

2022-01-01